The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2010
Antidepressant medication and executive dysfunction: a deleterious interaction in late-life depression.
СтатьяМногоцентровое исследованиеРандомизированное исследованиеПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sneed Joel R, Culang Michelle E, Keilp John G, Rutherford Bret R, Devanand Davangere P, Roose Steven P
Аннотация
OBJECTIVES: To determine whether there is differential response to placebo or citalopram among older patients with and without deficient response inhibition (DRI).
DESIGN: This is an 8-week, double-blind, placebo-controlled trial.
SETTING: Outpatient psychiatry.
PARTICIPANTS: Unipolar depressed patients aged 75 years and older.
INTERVENTION: Citalopram (20-40 mg/day) or placebo pill.
MEASUREMENTS: Baseline Stroop Color-Word Test and weekly 24-item Hamilton Rating Scale for Depression assessments.
RESULTS: Citalopram-treated patients with DRI did significantly worse than placebo-treated patients with DRI. Conversely, citalopram-treated patients without DRI did significantly better than placebo-treated patients without DRI.
CONCLUSION: Patients with late-life depression and DRI respond worse to selective serotonin reuptake inhibitor (SSRI) than placebo. These findings suggest that there may be a deleterious interaction between DRI and antidepressant medication in late-life depression and that the mechanism of SSRI and placebo response is different.
DESIGN: This is an 8-week, double-blind, placebo-controlled trial.
SETTING: Outpatient psychiatry.
PARTICIPANTS: Unipolar depressed patients aged 75 years and older.
INTERVENTION: Citalopram (20-40 mg/day) or placebo pill.
MEASUREMENTS: Baseline Stroop Color-Word Test and weekly 24-item Hamilton Rating Scale for Depression assessments.
RESULTS: Citalopram-treated patients with DRI did significantly worse than placebo-treated patients with DRI. Conversely, citalopram-treated patients without DRI did significantly better than placebo-treated patients without DRI.
CONCLUSION: Patients with late-life depression and DRI respond worse to selective serotonin reuptake inhibitor (SSRI) than placebo. These findings suggest that there may be a deleterious interaction between DRI and antidepressant medication in late-life depression and that the mechanism of SSRI and placebo response is different.